Evidence · 6 min read

12-month clascoterone data: keep applying or lose the gain

Hair count kept rising through month 12 on drug. Men switched to vehicle after month 6 gave hair back. That is a maintenance drug, not a course of antibiotics.

The finding

On 15 April 2026 Cosmo reported the 12-month Phase 3 extension. Men who remained on clascoterone 5% for the full year achieved a statistically significant 2.39-fold greater improvement in Target Area Hair Count than men who received active drug for six months and vehicle from month 7 to 12.

Gains were visible from around month 3 and continued through month 12 — company language was “without plateau.” The switched group declined after stopping. Patient satisfaction at month 12 was +24.5% relative versus vehicle groups.

Why it matters

Every successful AGA drug so far is a subscription for the life of the follicle. Finasteride and minoxidil both give hair back when you quit. Clascoterone is advertising the same biology: block the signal, keep the hair; remove the block, miniaturisation resumes.

That is disappointing if you wanted a cure. It is expected if you understand androgenetic alopecia. It is also how Cosmo argues for chronic-use labelling and a durable commercial product.

Chronic-use safety (topline)

Twelve-month tolerability was described as comparable to vehicle. No meaningful systemic endocrine signal in the company’s disclosure. Local scalp reactions were the events to watch, as with any leave-on solution. Full tables belong in the NDA and the eventual paper — not in a press release.

What happens next

Cosmo has said it is preparing a US NDA and an EU MAA, with the American filing aimed at early 2027. Review clocks are measured in months, not weeks. A 2027 filing does not mean a 2027 bottle in every pharmacy. Track the calendar on when it may be available.